Stealth BioTherapeutics had expected the FDA to respond on Tuesday to its marketing application for elamipretide to treat ...

If the law is struck down or any ambiguity left surrounding its validity, coverage of and access to preventive care like PrEP ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

With a May 24 deadline looming, Kennedy's MAHA commission has held just one full meeting on its goal of reducing childhood ...

Many Medicare quality measures are only loosely related to actual patient outcomes. It’s time to deregulate the system, ...

For the second consecutive year, the pharma industry saw its reputation dip among patient advocacy groups, largely due to ...

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

A close look at Chris Klomp's path to the top of Medicare, which pays for the health care of 68 million Americans.

While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...